

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(use as many sheets as necessary)

Sheet 1 of 2**Complete if Known**

Application Number	10/088,724
Filing Date	March 18, 2002
First Named Inventor	Nishimoto
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082377-000000US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear



RECEIVED

AUG 16 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
OC	AA	WO	01/21786	A1 ✓	03-29-2001			yes
OC	AB	WO	00/14204	A1 ✓	03-16-2000			yes

Examiner
Signature

Date
Considered

3/11/4

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3230118 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2**Complete If Known**

Application Number	10/088,724
Filing Date	March 18, 2002
First Named Inventor	Nishimoto
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082377-000000US

RECEIVED

AUG 16 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC ¹	BRENNEMAN et al., "Activity-Dependant Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides," <u>J. Pharmacology Exp. Therapeutics</u> , 285(2): 619-627 (1998).	
	AD	BRENNEMAN et al., "A Femtomolar-acting Neuroprotective Peptide," <u>J. Clinical Investigation</u> , 97(10): 2299-2307 (1996).	
	AE	DORE et al., "Insulin-like growth factor I protects and rescues hippocampal neurons against β -amyloid- and human amylin-induced toxicity," <u>PNAS</u> , 94:4772-4777 (1997).	
	AF	GUO et al., "Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: Reduced oxidative stress and preserved mitochondrial function," <u>PNAS</u> , 95: 3227-3232 (1998).	
	AG	GUO et al., "Secreted β -Amyloid Precursor Protein Counteracts the Proapoptotic Action of Mutant Presenilin-1 by Activation of NF - κ B and Stabilization of Calcium Homeostasis*," <u>J. Biological Chemistry</u> , 273(20):12341-12351 (1998).	
	AH	MARK et al., "Basic FGF attenuates amyloid β -peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na ⁺ /K ⁺ -ATPase activity in hippocampal neurons," <u>Brain Research</u> , 756:205-214 (1997).	


Examiner
SignatureDate
Considered

3/11/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3230118 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Completeness of Known			
		Application Number	10/088,724		
		Filing Date	March 18, 2002		
		First Named Inventor	Nishimoto		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	082377-000000US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
OC	AA	MATTSON et al., "Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1," <u>NeuroReport</u> , 8:3817-3821 (1997).	

RECEIVED
AUG 16 2002
TECH CENTER 1600/2900

Examiner Signature	<i>[Signature]</i>	Date Considered	3/11/04
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3233848 v1